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Abstract
Background: To investigate whether B-type natriuretic peptide (NP)-guided treatment of heart failure (HF) patients
improved their health related quality of life (Hr-QoL) compared to routine HF treatment, and whether changes in
Hr-QoL differed depending on whether the patient was a responder to NP-guided therapy or not.
Methods: A secondary analysis of the UPSTEP-study, a Scandinavian multicentre study using a prospective,
randomized, open, blinded evaluation design on patients with HF with New York Heart Association (NYHA) class II-IV.
NP-guiding was aimed to reduce BNP <150 ng/L if < 75 years or BNP < 300 ng/L if > 75 years. A responder was defined
as a patient with a BNP < 300 ng/L and/or a decrease in BNP of at least 40 % in week 16 compared to study start. Short
form-36 (SF-36) was used to measure Hr-QoL. At the study start, 258 patients presented evaluable SF-36 questionnaires,
131 in the BNP group and 127 in the control group. At the study end 100 patients in the NP-guided group and 98 in
the control group, presenting data from both the study start and the study end.
Results: There were no significant differences in Hr-QoL between NP-guided HF treatment and control group;
however significant improvements could be seen in four of the eight domains in the NP-guided group, whereas in the
control group improvements could be seen in six of the domains.
Among the responders improvements could be noted in four domains whereas in the non-responders improvements
could be seen in only one domain evaluating within group changes.
Conclusions: Improved Hr-QoL could be demonstrated in several of the domains in both the NP-guided and the
control group. In the responder group within group analyses showed more increased Hr-QoL compared to the non-
responder group. However, all groups demonstrated increase in Hr-QoL.
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Background
In developed countries, approximately 1-2 % of the adult
population has heart failure (HF) and the prevalence is
over 10 % among persons older than 70 years of age [1].
There was an increase in the absolute numbers of patients
hospitalized because of HF in Sweden between 1990 until
2007, but the age-adjusted prevalence in Sweden has
shown a decreasing trend since 2002 [2]. Improved diag-
nostics, pharmacological therapies and interventions on
patients with cardiovascular (CV) diseases have resulted
in a decrease in the incidence of HF after acute myocardial
infarction in Sweden [3]. However, despite recent im-
provements in pharmacological treatment, the prognosis
is poor, with an estimated five-year survival of approxi-
mately 50 % [4]. Moreover, HF patients’ perceived health-
related quality of life (HR-QoL) is poorer compared to
patients with other chronic diseases [5].
There have been several attempts to improve and
individualize HF treatment through guiding with natri-
uretic peptides (NP). Troughton et al. showed that NP-
guided HF therapy reduced all-cause mortality as well as
HF and CV hospitalization in patients younger than
75 years [6]. However, only mortality and hospitalization
were evaluated, and in a review article by Anker et al. the
importance of patient-reported outcomes such as Hr-QoL
was emphasized, and it was recommended that these out-
comes should be reported in all clinical CV trials, in
addition to mortality and morbidity [7]. There are only a
limited number of NP-guided studies that have evaluated
the impact of NP-guiding on Hr-QoL [8–13]. Bhardwaj
et al. showed that NT-proBNP-guided care was associated
with greater and more sustained improvement in Hr-QoL
compared to standard of care [11]. However, an association
between NP-guiding and improvement in Hr-QoL was not
reported in five other NP-guiding studies [8–10, 12, 13].
One reason for the differences in study findings may be
that not all HF patients seem to benefit from NP-guided
therapy, i.e. their NP levels do not decrease despite in-
creased doses of angiotensin-converting enzyme inhibitors,
angiotensin II receptor blockers, beta-blockers and min-
eralocorticoid receptor antagonists. Thus, these patients,
defined as non-responders to HF pharmacological treat-
ment, may have obscured the effects of NP-guided ther-
apy on Hr-QoL. Gaggin et al. [14] and the UPSTEP study
[15, 16] have previously shown that the responders had
significantly reduced risk of CV- and HF hospitalization
and CV- and HF mortality compared to non-responders.
However, to our knowledge no studies have reported
whether responders to NP-guided HF treatment also show
beneficial effects of their treatment on Hr-QoL.
Aim
The primary aim was to investigate whether B-type natri-
uretic peptide-guided treatment of HF patients compared
to routine HF treatment improves the perceived Hr-QoL.
The secondary aim was to evaluate whether changes in
HR-QoL differed depending on whether the patient was a
responder to NP-guided therapy or not.
Methods
Population
This study is based on data from the UPSTEP-study and
has been described elsewhere [15]. In brief, the UPSTEP
study was a Scandinavian multicentre study (15 centres
in Sweden and four centres in Norway), on patients with
HF with New York Heart Association (NYHA) class II-IV,
using a PROBE design (prospective, randomized, open,
blinded evaluation) [15]. The patients were randomized
into a BNP-guided treatment group (BNP group) and a
control group (conventionally treated), (CTR group). In
the CTR group, medical treatment was adjusted at the dis-
cretion of the investigator based on changes in signs and/
or symptoms of worsening HF, in accordance with the
guidelines [15].The patients were recruited after an epi-
sode of worsening HF and a verified left ventricular ejec-
tion fraction (LVEF) < 40 %, NYHA class II–IV and a
BNP > 150 ng/L if < 75 years, and >300 ng/L if >75 years,
were required to be included. Most patients were in
NYHA functional class III (55 %) and 14 % were in NYHA
class IV. The mean values of BNP were 808 ng/L in the
BNP group and 899 ng/L in the CTR group at the study
start (Table 1). Both groups were well treated at baseline
regarding HF medication. In the BNP group 146 out of
147 patients (99 %) were receiving treatment with renin-
angiotensin system (RAS)-blockers versus 129 of 132 pa-
tients (98 %) in the CTR group. Approximately 50 percent
of those in both groups had impaired renal function de-
fined as an estimated Glomerular Filtration Rate (eGFR) <
60 mL/min/1.73 m2 [15].
Definition of a responder
The definition of a responder was carefully evaluated
with different percentage changes in different weeks,
and the best definition to a responder was a patient with
a decrease in BNP concentration of at least 40 percent
in week 16 of follow-up, compared to study start and/or
a BNP < 300 ng/L in week 16 [16]. According to that
definition, 78 responders (60 %) and 53 non-responders
could be identified (Fig. 1). In the conventionally treated
group, it was not allowed to control BNP, so responders
and non responders are derived from the BNP-group,
(Fig. 1). The non-responders had a greater degree of im-
paired renal function compared to the responders (eGFR
56.1 vs. 66.5; p = 0.005) and the non-responders were
older (74.0 years vs. 69.6 years; p = 0.009) (Table 1). There
were no differences in medication, blood pressure, heart
rate, serum-potassium or BNP levels between the re-
sponders and non-responders at study start [16].
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Health-related Quality of life
The patients’ self-assessed Hr- QoL was measured using
the Swedish and Norwegian version of the SF-36 [17, 18].
SF-36 is a well-established Hr-QoL instrument and is fre-
quently used in studies of patients with HF and other dis-
eases [19, 20]. The 36-item instrument includes eight
domains of Hr-QoL: physical functioning (PF), role limita-
tions due to physical health problems (RP), bodily pain
(BP), general health (GH), vitality (VT), social functioning
(SF), role limitations due to emotional health problems
(RE) and mental health (MH). The scores were trans-
formed into values between 0-100, with a higher score in-
dicating a better Hr-QoL [21]. The physical component
score (PCS) and mental component score (MCS), are two
higher order components [17]. All patients filled out the
inventory at the study start and at the study end. We
used a normative Swedish population evaluated with SF-
36 to illustrate the effect ageing has on Hr-QoL. The
population 65-74 years consisted of 460 males and 481
females and the population over 75 years of 108 males
and 125 females [22].
BNP analyses
BNP analyses were analysed on site by means of an im-
munoassay technique (Triage, Biosite Inc., San Diego,
CA, USA) as described in a previous publication [15].
Statistics
Continuous variables were presented as means and stand-
ard deviation (SD) values and categorical variables were
Table 1 Baseline characteristics for conventionally treated (CTR group) and patients whose treatment was guided by BNP (BNP group)
and for non-responders and responders (defined as a patient with a BNP < 300 ng/l and/or a decrease in BNP of at least 40 % in week
16 compared to BNP at study start) (ref art 2)
Characteristics BNP group CTR group p-value Responders Non-responders p-value
n = 147 n = 132 n = 78 n = 53
Background
Age years (SD) 71.6 (±9.7) 70.1 (±10) 0.19 69.6 (±10.2) 74.0 (±8.1) 0.009
Gender male, n (%) 107 (73 %) 96 (73 %) 0.99 63 (81 %) 34 (64 %) 0.33
IHD n (%) 81 (55 %) 76 (58 %) 0.68 43 (55 %) 30 (57 %) 0.87
Hypertension n (%) 39 (27 %) 30 (23 %) 0.46 35 (45 %) 25 (47 %) 0.80
Diabetes Mellitus n (%) 39 (27 %) 48 (36 %) 0.08 19 (24 %) 13 (25 %) 0.98
Physical examination
Heart rate beats/min (SD) 74 (±18) 73 (±19) 0.89 78 (±20) 71 (±15) 0.93
Systolic blood pressure, mm Hg (SD) 126 (±22) 122 (±22) 0.12 126 (±23) 125 (±21) 0.77
Diastolic blood pressure, mm Hg (SD) 75 (±13) 74 (±13) 0.42 75 (±13) 74 (±12) 0.71
NYHA functional classes
II n (%) 47 (32 %) 36 (27 %) 0.39 28 18 0.09
III n (%) 76 (52 %) 78 (59 %) 0.22 42 27 0.74
IV n (%) 22 (15 %) 18 (14 %) 0.75 8 8 0.41
Medication
ACEi n (%) 113 (77) 92 (70) 0.17 65 (83) 37 (70) 0.67
ARB n (%) 51 (35) 46 (35) 0.98 23 (29) 23 (43) 0.10
BB n (%) 137 (93) 125 (95) 0.60 75 (96) 48 (91) 0.19
MRA n (%) 81 (55) 78 (59) 0.50 43 (55) 28 (55) 0.80
Echocardiography (LVEF)
<30 % n 84 (57 %) 76 (58 %) 0.94 50 (64 %) 27 (51 %) 0.13
30-40 % n 63 (43 %) 56 (42 %) 0.94 28 (36 %) 26 (49 %) 0.13
Laboratory results
BNP ng/l mean (SD) 808 (±676) 899 (±915) 0.34 805 (±704) 778 (±651) 0.82
eGFR mL/min/1.73 m2 mean (SD) 61.4 (±20.9) 60.1 (±20.9) 0.59 66.5 (±21.1) 56.1 (±19.2) 0.005
Potassium mmol/l mean (SD) 4.3 (±0.5) 4.2 (±0.5) 0.38 4.3 (±0.50) 4.3 (±0.52) 0.80
Notes: ACEi Angiotensin Converting Enzyme inhibitor, ARB Angiotensin receptor blockers, BB Beta blocker, BNP B-type natriuretic peptide, CTR Conventionally
treated, eGFR estimated glomerular filtration rate (MDRD formula), IHD Ischemic Heart Disease, LVEF Left Ventricular Ejection Fraction, MRA mineralocorticoid receptor
antagonist, NYHA New York Heart Association functional class, SD standard deviation
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presented using percentages. Differences in mean values
between groups were analysed using the Student’s two-
tailed T-test for normal distributed data. For non-normal
distributed variables, the non-parametric Mann–Whitney
U-test was used. Continuous variables were analysed with
the student unpaired two-sided T-test, whereas the χ 2-test
was used for discrete variables. Within group differences
were analysed with a Wilcoxon paired test. Spearman
Rank Order correlations was used to analyse possible cor-
relations between background characteristics and changes
in Hr-QoL as indicated by the composite scores PCS and
MCS. A p-value <0.05 was considered statistically signifi-
cant. All calculations were performed on commercial stat-
istical software packages (Statistica v.10,Statsoft Inc, Tulsa,
OK, USA).
Ethical considerations
The study protocol of UPSTEP was approved by the
Regional Ethical Committee (Diary nr: M180-04) in
Linkoping, Sweden. Every patient signed an informed




The total study population consisted of 279 patients, of
whom 147 were randomized to the BNP-guided group
and 132 patients to the CTR group. The mean follow-up
time of the 198 patients who completed the study was
712 (SD ± 279) days. Eleven patients, seven in the BNP
group and four in the control group, discontinued the
study for various reasons (Fig. 1), mainly because of un-
willingness to continue [15]. At the study start, 258 pa-
tients presented evaluable SF-36 questionnaires, 131 in
the BNP group and 127 in the control group. As seen in
Table 1, no significant differences between the groups
regarding baseline characteristics were found. At the
study end there were 100 patients in the BNP-guided
group and 98 in the control group, presenting evaluable
questionnaires from both the study start and the study
end.
Of the 147 patients who were randomized to the BNP
group in the UPSTEP study, there were 78 responders
and 53 non-responders who had answered the Hr-QoL
questionnaire at the study start (Fig. 1). The responders
Fig. 1 Flow chart of the patients in the UPSTEP-study. Conventionally treated (CTR group) and BNP group, BNP group divided into responders
and non-responders. Responder defined as a patient with a BNP under 300 ng/l and/or a decrease in BNP of at least 40 percent in week 16 of
follow-up, compared to study start
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had a mean follow-up time of 649 days (SD ± 268) and
non-responders 640 (SD ± 365) days (p = 0.86). The co-
hort of patients with SF-36 questionnaires available at
both the study start and at the final visit consisted of 68
responders with 675 days (SD ± 266) of follow-up and 32
non-responders with 794 days (SD ± 286) of follow
up, p = 0.04. The total numbers of worsening HF was 57
in the CTR-group versus 41 in BNP-group, and the
amount of serious adverse events was 301 events versus
252 events in BNP group.
Health-related Quality of life BNP-guided and CTR group
Figure 2 presents the change in perceived Hr-QoL dur-
ing the study. No significant differences between the
groups at baseline regarding scores in the eight dimen-
sions could be noted (Appendix 1).
Within-group analyses of changes from the study start
showed that significant improvements could be found in
four of the eight domains in the NP-guided group
(PF, p < 0.01, RP, p < 0.01, VT, p < 0.001 and MH, p <
0.01). In the CTR group, significant improvements could
be seen in six of the eight domains (RP, p < 0.001, BP, p <
0.001, VT, p = 0.03, SF, p < 0.0001, RE, p < 0.01, MH, p <
0.01) (Appendix 2). For the composite dimension scores
PCS and MCS, the NP-guided group improved signifi-
cantly in PCS, (p < 0.001) whereas those with conventional
treatment improved in the PCS (p < 0.001), and MCS (p <
0.002) (Appendix 2).
Health-related Quality of life responders and
non-responders
Figure 3 shows the mean changes of the scores be-
tween the study start and the study end in the eight
different SF-36 domains including the PCS and MCS.
Compared to non-responders, the responders at the
study start already had significantly better scores in
three of the eight SF-36 domains (PF (p = 0.001), GH
(p = 0.01), SF (p = 0.006) and in the summary score
PCS (p = 0.007) (Appendix 1). Within group analyses
of changes from the study start showed significant
improvements for responders in four domains; RP (p <
0.004), VT (p < 0.002), SF (p = 0.03), MH (p = 0.02) and
for PCS (p < 0.004). For the non-responders the within
group analysis was significantly improved in one domain;
PF (p = 0.03) and for the summary score, PCS (p < 0.03)
(Appendix 2).
Correlates of patient characteristics to changes in
Health-related Quality of life
Few background characteristics correlated significantly
to changes in PCS and MCS. Instead of presenting data
on eight dimensions we presented the two summary
scores PCS and MCS. In the total study group (i.e. NP-
guided and CRT group), a higher heart rate correlated
weakly with improvements in PCS (r = 0.23) and MCS
(r = 0.25) whereas a previous myocardial infarct correlated
weakly to a worse MCS (r = -0.23), In the 100 patients de-
fined as responders or non-responders, no significant cor-
relations were found.
Discussion
The main finding is that BNP guided HF therapy did
not improve the perceived Hr-QoL compared to the
conventionally guided HF therapy. However, the BNP
group improved in four out of the eight domains,
whereas the CTR groups improved in six of the eight
domains. We could also demonstrate that the responders
improved in four of the eight domains, whereas among
the non-responders improvement could only be seen
in one single domain. It could also be demonstrated
Fig. 2 Change in Health-related Quality-of-Life between the NP-guided group (BNP group, n = 100) and conventionally treated (CTR group, n = 98)
group at the study start and the study end regarding different dimensions of the SF-36 questionnaire
Karlström et al. BMC Cardiovascular Disorders  (2016) 16:39 Page 5 of 10
that improvements could be seen irrespective if BNP
guided therapy were applied, or if randomized to con-
ventional therapy. Even if a difference could be seen
in the size of improvement between responders com-
pared to non-responders, all groups did improve in
Hr-QoL. The mechanism behind this could only be
speculated on, but it is independent of the use of
BNP-guided therapy.
The fact that NP-guided therapy group did not im-
prove in the perceived Hr-QoL compared to the conven-
tionally guided therapy group concurs with studies that
have addressed Hr-QoL and NP-guiding [8–10, 12, 13].
However, the Pro-B Type Natriuretic Peptide Outpatient
Tailored Chronic Heart Failure (PROTECT) study did
present improved HR-QoL [11]. That study showed that
those receiving NP-guided medical treatment had a
greater and more sustained improvement in HR-QoL
compared to those who received conventional handling
of their HF. However, our study and the PROTECT
study differed in populations and in study design, which
may partly explain the differences regarding the per-
ceived Hr-QoL. The patients in the PROTECT study
were around 64 years of age, whereas the mean age of
our patients was 71 years, thus ours was an older popu-
lation. As it is documented that with increased age, a de-
crease in Hr-QoL is to be expected, the margin to
influence this variable diminishes as the population is
getting older.
We converted our BNP levels to an estimated NT-
proBNP level. We found that the UPSTEP population
had higher levels of NT-proBNP compared to the
population in PROTECT study. Thus, the present
study population was older and had higher NT-
proBNP concentrations, indicating a more severe HF
compared to the PROTECT population. It is therefore
possible that our study population was less likely to
benefit from the BNP-guided therapy, and thus lesser
differences were reported between the two groups in
the perceived Hr-QoL. In the evaluation, the score
differences between the different groups are small,
however as the patients evaluated are elderly and the
progress of Hr-QoL can be expected to decrease even
small difference can therefore be of importance. In
our study we have demonstrated that the responders
survive in a higher percentage compared to non-
responders [16]. Therefore the demonstration of small
differences in domains could be adequate in this pa-
tient population.
It has been discussed in the literature a potential ad-
vantage using a disease-specific Hr-QoL instrument in
terms of better sensitivity for small changes in HF symp-
toms compared to a generic instrument. One of the
most well-known disease specific instrument in the area
of HF is the Minnesota Living with Heart Failure
(MLWHF) [11]. However, there are studies indicating is
a better ability to differentiate physical and emotional as-
pects of HR-QoL by SF-36 compared to MLwHF [23].
In the study Trial of Intensified versus standard Medical
therapy in Elderly patients with Congestive Heart Failure
(TIME-CHF), MLwHF and SF-12, were used to evaluate
HR-QoL [9]. The result were consistent with ours, im-
provement of Hr-QoL within the two groups during the
Fig. 3 Change in Health-related Quality-of-Life between the responders (n = 68) and non-responders (n = 32) at the study start and the study end
regarding different dimensions of the SF-36 questionnaire
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first 12 months, but after that no significant differences
between the NP-guided and the control group. This
could be interpreted as perceived improvement in Hr-
QoL can be detected with both generic and disease spe-
cific Hr-QoL instrument if represented by SF-12 and
MLWHF. In our study we used the SF-36, but there is
no reason to believe that there are fundamental differ-
ences in this perspective between the two instruments.
Interestingly, all four groups (i.e. the BNP-guided group,
the CTR group, responders and non-responders) investi-
gated had improved Hr-QoL. This is interesting since it
might be expected that patients with a severe chronic
and disabling disease such as HF over time at best may
have shown a maintained or a slowly decreased Hr-QoL
level. In the Prospective Comparison of ARNI (Angioten-
sin Receptor–Neprilysin Inhibitor) with ACEI (Angioten-
sin-Converting–Enzyme Inhibitor) to Determine Impact
on Global Mortality and Morbidity in Heart Failure Trial
(PARADIGM-HF) study [24], the control group, despite
being on optimal treatment, had a significantly decreased
Hr-QoL, indicating that Hr-QoL are to be expected to de-
crease in patient with HF in spite of continuous pharma-
cologic treatment. In healthy elderly persons the Hr-QoL
also decreases as a result of increased age (Fig. 4 ) [22]. In
our study, the study population had an age of 71 years at
the study start and the follow-up time was almost two
years. Instead of an expected decline in the eight domain
scores during the study, we saw an improvement in both
groups.
HR-QoL is an important tool to determine whether
different treatment actions are of any benefit for the pa-
tients. Wyrwich et al. evaluated the smallest amount on
the SF-36 scale score that would show that a patient
moved up or down one response level of the scale items.
[25] The smallest points in a state change which
represents the smallest amount that an SF-36 scale
would change if a patient moved up or down one re-
sponse level on only one of the SF-36 scale items are; PF
5 points, RH 6.25 points, BP 10 points, GH 5 points, VT
6.25 points, SF 12.5 points, RE 8.33 points and MH 5
points [25]. According to Wyrwich definition the CTR
group moved up one response level in PF, RP, BP, VT,
SF, RE and the BNP-guided group moved up in PF, RP,
VT and MH. The responders moved up in RP, VT, MH
and non responders in PF, RP VT and MH. There was
no response down in any of the four groups (Table 2).
The exact mechanisms behind the improvements in
Hr-QoL are not easy to explain. However, support from
health care professionals has been found to be an im-
portant factor influencing HF patients’ Hr-QoL [26].
Thus, all patients had scheduled visits at weeks 2, 6, 10,
16, 24, 36, 48 and then every six months until the study
end where they met the HF nurse/doctor at the HF
clinic. This is more often than clinical routine in the
Nordic countries. The mechanism that more use of
health resources also influences the perceived Hr-QoL in
HF patients has also been reported from primary health
care [27, 28]. In the present study NP-guiding has been
shown to improve the perceived Hr-QoL in patients with
HF. As the perceived Hr-QoL is a complex mechanism
other factors also influences the reported result, as seen
in this study from the group with conventional HF-
treatment where improvement of Hr-QoL was equally
reported.
As the design of the present study does not permit
the differentiation between effect of the NP-guiding,
and the effect of contacts with the HF-professionals,
we suggest further research in this important area.
From the patient perspective increased Hr-QoL was re-
ported, an important difference compared to what was
Fig. 4 SF 36 scores for a normative Swedish population in the eight domains at age 65-74 years and a population older than 75 years [22], showing
decreasing scores in all eight domains with increasing age
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expected. Therefore more research in this important
area is suggested.
Study limitations
There are limitations to this study that need to be dis-
cussed; the relatively small size of the study popula-
tion restricts the possibilities for drawing conclusions.
The population consisted of a homogenous Caucasian
population. Therefore it is not possible to draw con-
clusions about other populations; the age of the study
population was high, why the obtained results might
be difficult to apply to a general population with HF
in the society. The Hr-QoL questionnaire was only
filled out at study start and at study end this might
influence the possibility to detect changes during the
study. The use of a non-disease-specific quality-of-life
instrument limits the interpretation of small changes
in Hr-QoL.
Conclusion
Hr-QoL improved in several domains in both the NP-
guided therapy group and the control group. Compar-
ing the responder group to the non-responder group,
the within group analyses showed improvements in
four out of eight domains in the responder group
compared to one out of eight domains in the non-
responder group.
The perceived Hr-QoL is a complex mechanism
that is influenced not only by the pharmacological
treatment given, but also by the repeated contacts
with health professionals. Both components positively
influenced the Hr-QoL in the patients in this study.
Therefore more research in perceived Hr-QoL and
how to influence it is suggested.
Appendix 1
Table 2 The clinically important difference for each SF-36 scale
to indicate that the patient moved up (+) or down (-) one
response level on only one of the scale items [25] in BNP-guided












PF 5 + + 0 +
RP 6.25 + + + +
BP 10 + 0 0 0
GH 5 0 0 0 0
VT 6.25 + + + +
SF 12.5 + 0 0 0
RE 8.33 + 0 0 0
MH 5 0 + + +
Abbreviations: PF Physical functioning, RP Role limitations due to physical
health problems, BP Bodily pain, GH General health, VT Vitality, SF Social
functioning, RE Role limitations due to emotional health problems, MH Mental
health, BNP B-type natriuretic peptide, CTR conventionally treated group, SF-36
Short Form 36
Note: aA state change represents the smallest amount that an SF-36 scale
score would change if a patient moved up (+) or down (-) one response level
on only one of the scales items according to Wyrwich et al.
Table 3 Short Form-36 (SF-36) for conventionally treated (CTR) and patients whose treatment was guided by BNP and for responders
and non-responders at study start and at study end. Responder defined as a patient with a BNP under 300 ng/l and/or a decrease in
BNP of at least 40 percent in week 16 of follow-up, compared to study start
Study start Study end Study start Study end
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
CTR group BNP group p CTR group BNP group p Responders Non-responders p Responders Non-responders p
n = 127 n = 131 n = 98 n = 100 n = 78 n = 53 n = 68 n = 32
SF-36
PF 46.4 (±27) 45.3 (±26) 0.80 54.8 (±26) 55.2 (±27) 0.78 51.3 (±25) 36.5 (±24) 0.001 52.7 (±26) 42.3 (±23) 0.055
RP 19.1 (±33) 28.4 (±38) 0.06 39.8 (±44) 46.4 (±44) 0.21 32.4 (±38) 22.6 (±37) 0.15 33.5 (±44) 22.7 (±38) 0.20
BP 56.4 (±31) 60.6 (±29) 0.26 65.8 (±29) 69.6 (±29) 0.39 62.7 (±29) 57.4 (±29) 0.32 64.6 (±29) 64.2 (±30) 0.95
GH 47.1 (±20) 48.5 (±18) 0.45 50.9 (±20) 53.8 (±19) 0.51 51.8 (±18) 43.8 (±17) 0.01 52.2 (±20) 45.5 (±17) 0.07
VT 43.1 (±22) 42.0 (±21) 0.61 50.2 (±25) 51.9 (±22) 0.63 43.3 (±22) 40.2 (±19) 0.40 42.5 (±25) 43.0 (±18) 0.91
SF 62.4 (±25) 67.8 (±25) 0.10 75.1 (±24) 73.8 (±25) 0.60 72.6 (±25) 60.5 (±23) 0.006 72.6 (±24) 62.5 (±22) 0.056
RE 41.1 (±45) 49.0 (±45) 0.19 54.5 (±44) 57.1 (±42) 0.75 52.8 (±44) 43.4 (±45) 0.24 55.7 (±44) 44.8 (±45) 0.26
MH 70.0 (±20) 69.6 (±19) 0.82 74.1 (±19) 76 (±17) 0.61 70.1 (±18) 68.8 (±20) 0.69 70.1 (±19) 69.5 (±19) 0.87
PCS 31.5 (±11) 32.7 (±11) 0.24 35.6 (±11) 37.8 (±12) 0.18 34.9 (±10) 29.6 (±11) 0.007 35.5 (±11) 31.6 (±11) 0.09
MCS 42.7 (±12) 43.6 (±11) 0.60 46.0 (±11) 46.5 (±10) 0.87 44.3 (±11) 42.7 (±11) 0.45 44.3 (±11) 43.1 (±11) 0.63
Abbreviations: PF Physical functioning, RP Role limitations due to physical health problems, BP Bodily pain, GH General health, VT Vitality, SF Social functioning, RE
Role limitations due to emotional health problems, MH Mental health, PCS Physical component score, MCS Mental component score, SD Standard Deviation
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Appendix 2
Abbreviations
ACEI: Angiotensin-Converting–Enzyme Inhibitor; ARNI: Angiotensin Receptor–
Neprilysin Inhibitor; BNP: B-type natriuretic peptide; BNP-group: BNP-guided
group; BP: bodily pain; CTR-group: conventional treated group;
CV: cardiovascular; GH: general health; HF: heart failure; Hr-QoL: health
related quality of life; MCS: mental component score; MH: mental health;
MLWHF: Minnesota Living with Heart Failure; NP: natriuretic peptide;
NYHA: New York Heart Association; PARADIGM-HF: prospective comparison
of ARNI with ACEI to determine impact on global mortality and morbidity in
heart failure; PCS: physical component score; PF: physical functioning;
PROBE: prospective, randomized, open, and blinded evaluation;
PROTECT: Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart
Failure; RE: role limitations due to emotional health problems; RP: role
limitations due to physical health problems; SD: standard deviation; SF: social
functioning; SF-36: Short Form 36; TIME-CHF: The Trial of Intensified vs
Standard Medical Therapy in Elderly Patients With Congestive Heart Failure;
UPSTEP: Use of PeptideS in Tailoring hEart failure Project; VT: vitality.
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